Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs GT Biopharma, Inc. (GTBP)

Adaptimmune Therapeutics PLC and GT Biopharma, Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and GT Biopharma, Inc. are of similar size ($15.2M and $14.6M). Adaptimmune Therapeutics PLC grew revenue faster over the last twelve months: −54.0% against −76.2%. GT Biopharma, Inc. has the higher net margin (0.00% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Adaptimmune Therapeutics PLC leads on 8 and GT Biopharma, Inc. on 8.

Valuation

Metric ADAPY GTBP Biotechnology median
P/E n/m n/m 8.50
P/S 0.12 181.94 9.71
P/B n/m 3.06 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.12 542.75 9.21
Earnings yield (2,166.67%) (2,098.15%) (33.15%)
Free cash flow yield (2,380.45%) (130.63%) (25.50%)

Profitability

Metric ADAPY GTBP Biotechnology median
Gross margin 94.81% 41.67% 65.16%
Operating margin (427.75%) 0.00% 0.00%
Net margin (262.46%) 0.00% 0.00%
Free cash flow margin (288.20%) 0.00% 0.00%
Return on equity (1,349.52%) 102.03% (56.36%)
Return on assets 0.00% (176.27%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY GTBP Biotechnology median
Revenue growth (TTM) (53.99%) (76.19%) 6.02%
EPS growth (last fiscal year) 142.86% 3.75% 30.26%
Revenue growth, 5-year CAGR 8.40% 19.67% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY GTBP Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 2.61 4.72
Net debt to EBITDA 0.47 0.56 0.96

Dividend

Metric ADAPY GTBP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADAPY GTBP Biotechnology median
Market cap 14.55m 15.17m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack